<i>In vivo</i> KRAS G12D/V degradation mediated by CANDDY using a modified proteasome inhibitorSatoshi Imanishi(Tokyo University of Science), Etsuko Miyamoto‐Sato(Tokyo University of Science)bioRxiv (Cold Spring Harbor Laboratory)April 23, 202110.1101/2021.04.23.441075Cited by 4SaveCiteExport RISWatch citationsRelated PapersA First-Class Degrader Candidate Targeting Both KRAS G12D and G12V Mediated by CANDDY Technology Independent of Ubiquitination|Molecules|2023|11Chromatin Regulation by HP1γ Contributes to Survival of 5-Azacytidine-Resistant Cells|Frontiers in Pharmacology|2018|5